Orchid Pharma Limited — Important, 30-07-2025: Updates

Orchid Pharma is set to gain full global ownership of Enmetazobactam (EXBLIFEP/Orblicef). The company entered an agreement to acquire assets from Allecra Therapeutics GmbH (Germany) and received French court approval for its bid on assets of Allecra Therapeutics SAS. This strategic move consolidates all rights to the novel antibiotic, bringing the India-discovered molecule back to its origin. This acquisition is expected to drive global growth and expansion for the Orchid brand, proving financially beneficial for the company.